Kezar Life Sciences, Inc. 8-K

What Happened
Kezar Life Sciences, Inc. (KZR) and Aurinia Pharma U.S., Inc. (Aurinia) entered into an Agreement and Plan of Merger on March 30, 2026. Aurinia’s wholly owned subsidiary will commence a cash tender offer within 10 business days to buy all outstanding Kezar shares for $6.955 per share in cash plus one contingent value right (CVR) per share. The Offer will remain open for 20 business days and, if successful, Merger Sub will merge into Kezar under Delaware law with closing expected in Q2 2026. The Buyer’s obligation requires that holders tender a number of shares that, together with any shares owned by the buyer, equals at least one more than 50% of outstanding shares; there is no financing condition. A supporting stockholder (Tang Capital) holding ~9% agreed to tender.

Key Details

• Offer price: $6.955 per share in cash plus one CVR per share; Offer open 20 business days.
• CVR rights include potential cash payments tied to: Closing Net Cash > $50M (pro rata excess), proceeds from an existing Enodia APA, proceeds from Everest collaboration, monetization of legacy zetomipzomib assets, and specified legacy-asset milestones/royalties (e.g., $500k, $5M, $12.5M, $20M, $50M, plus 3% royalty), subject to conditions and expiration rules.
• Closing conditions include Minimum Tender Condition (>50% +1 share), Closing Net Cash ≥ $50 million, accuracy of company reps, and customary covenants; no financing condition.
• Equity award treatment: Company options vest immediately before offer close; in‑the‑money options receive cash equal to intrinsic value + one CVR per underlying share; out‑of‑the‑money options are cancelled; RSUs will vest and be converted to shares prior to closing. Company ESPP will terminate immediately prior to the Effective Time.
• Other items: Kezar agreed to a customary no‑shop with limited exceptions; a $1.2M termination fee applies in certain scenarios; Rights Agreement amended so Parent is not an “Acquiring Person” in connection with the merger.

Why It Matters
For Kezar stockholders, the deal provides an immediate, certain cash component of $6.955 per share plus potential additional value via non‑tradeable CVRs that pay only if specified cash, asset‑sale or milestone events occur. The offer requires a majority tender (>50% +1) and certain cash balance and representation conditions to close, so completion is not guaranteed. Treatment of options and RSUs means vested equity holders will receive cash or CVRs for in‑the‑money awards while out‑of‑the‑money options are cancelled. Investors should review the forthcoming Offer documents (Schedule TO) and Kezar’s Schedule 14D‑9 for full terms and timing before deciding whether to tender.